Clinical economics:  a method for prospective health resource data collection.
Information about the economic benefit of new drugs is becoming increasingly important for formulary considerations, reimbursement policies and related considerations.  Although economic benefits of drugs have been analysed and reported, the economic benefits of drugs have rarely been examined in the course of randomised therapeutic trials.  We designed a modular survey instrument, the Resource Utilisation Survey (RUS), to collect economic outcomes in prospective trials.  A pilot test of the RUS was conducted using clinical trial methods in a study of nizatidine versus placebo in preventing ulcers induced by nonsteroidal anti-inflammatory drugs.  The purpose of the pilot study was to evaluate the RUS instrument and corresponding study design issues in clinical trials for either acute or chronic diseases. With the lessons learned from the pilot study, the RUS has been used successfully in other ongoing clinical trials.
Eli Lilly and Company, Indianapolis, Indiana.
C
C
Copley-Merriman
L
L
Egbuonu-Davis
J G
JG
Kotsanos
P
P
Conforti
T
T
Franson
G
G
Gordon
D017850:Economics, Pharmaceutical; D006801:Humans; D016567:Nizatidine / Q000191:economics; D017063:Outcome Assessment, Health Care; D010437:Peptic Ulcer / Q000139:chemically induced / Q000188:drug therapy; D010865:Pilot Projects; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011795:Surveys and Questionnaires